Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results
Daix (France), Long Island City (New York, United States), September 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 half-year financial results on Thursday, September 22, 2022.
Inventiva’s 2022 half-year financial results will be published on Wednesday, September 21, 2022
at 4:00 pm (New York), 10:00 pm (Paris).
Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman, Chief Medical Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, on Thursday, September 22, 2022 at8:00 am (New York), 2:00 pm (Paris).
The conference call and the slides of the presentation will be webcast live at: https://edge.media-server.com/mmc/p/v5uzhkr8 and also available on Inventiva’s onwards in the “Investors” – “Financial results” section.
In order to receive the conference access information necessary to join the conference call, it is required to register in advance using the following link: https://register.vevent.com/register/BI3a0c8ee6960a4b7a9db4026550ff3f51.
In the 10 minutes prior to the call start time, participants will need to use the conference access information provided in the e-mail received at the point of registering (dial-in number and access code).
A replay of the conference call and the presentation will be available after the event at: http://inventivapharma.com/investors/financial-results-presentations/.
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.
The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORγ inverse agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.
The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.
VP of Global External Affairs
+1 240 620 9175
Tristan Roquet Montegon /
Aude Lepreux / Matthieu Benoist
+33 1 53 96 83 83
|Westwicke, an ICR Company|
Patricia L. Bank
+1 415 513 1284
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Brookfield Announces Upgrade to Debt Rating9.12.2022 21:50:28 CET | Press release
BROOKFIELD, NEWS, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM, TSX: BAM.A) (“Brookfield”) today announced that it has received an upgrade on its senior unsecured debt rating from Moody’s to A3 from Baa1, reflecting the strengthening and resiliency of the inflation-linked cash flows generated across Brookfield’s three core pillars – Asset Management, Insurance Solutions and its Operating Businesses. This rating will apply to Brookfield Corporation, which will be the new name of Brookfield Asset Management Inc., after the completion of the public listing and distribution of a 25% interest in Brookfield’s asset management business. Nicholas Goodman, Chief Financial Officer, stated, “We are pleased that the continued growth in our three core pillars, the stability and resiliency of the cash flows we generate, and our conservative capitalization is being recognized in the credit upgrade we received from Moody’s. This upgrade further reinforces the key diffe
Manager’s transactions9.12.2022 20:01:25 CET | Press release
December 9, 2022 – announcement no. 12 Shares received as a result of automatic reinvestment of dividends under short-term and long-term share-based incentive programs in Chr. Hansen Holding A/S administered by a third party. Please see attachment. For further information please contact: Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364 Cristina Rønde Hefting, Senior Investor Relations Manager, Tel: +45 4072 1224 Kathrine Westermann, Head of Media Relations, Tel: +45 2381 5595 Attachment No. 12 Managers transactions
ING reports outcome of 2022 EU-wide Transparency Exercise9.12.2022 18:16:45 CET | Press release
ING reports outcome of 2022 EU-wide Transparency Exercise ING Groep N.V. notes the announcements made today by the European Banking Authority and the European Central Bank (ECB) regarding the information of the 2022 EU-wide Transparency Exercise and fulfilment of the EBA Board of Supervisors’ decision. The EBA Board of Supervisors approved the package for the EU‐wide Transparency Exercise, which since 2016 is performed on an annual basis and published along with the Risk Assessment Report (RAR). The annual transparency exercise will be based solely on COREP/FINREP data on the form and scope to assure a sufficient and appropriate level of information to market participants. The outcome of the exercise related to ING Group can be found in the annexes of the EBA website. The templates were centrally filled in by the EBA and sent afterwards for verification by banks and supervisors. Banks had the chance to correct any errors detected and to resubmit correct data through the regular supervi
KBC Group: KBC report on the 2022 EBA Transparency Exercise9.12.2022 18:10:00 CET | Press release
Press Release Outside trading hours - Regulated information* Brussels, 9 December 2022 – after trading hours KBC report on the 2022 EBA Transparency Exercise KBC notes the announcements made today by the European Banking Authority (EBA) and the European Central Bank (ECB) regarding the publication of the EU-wide Transparency Exercise. The information of this 2022 EU-wide Transparency Exercise refers to the reported data as of 30 September 2021, 31 December 2021, 31 March 2022 and 30 June 2022. The templates, published on a bank-by-bank basis, are the following: Key MetricsLeverage ratioCapitalRisk exposure amountsP<otal Assets: fair value and impairment distributionLiabilitiesMarket RiskCredit RiskGeneral governments exposuresPerforming and Non-Performing exposuresForborne exposuresLoans and advances to non-financial corporations The data collection relies on the standard information reported by the banks to the EBA on a regular basis through the supervisory reporting framework (FINR
Ilkka Oyj – Acquisition of own shares on 9 December 20229.12.2022 18:05:09 CET | Press release
ILKKA OYJ, STOCK EXCHANGE RELEASE, 9 December 2022 at 19:00 EET IlkkaOyj – Acquisition of own shares on 9 December 2022 At Nasdaq Helsinki Ltd: Date9 December 2022Exchange transactionBuyShare trading codeILKKA2Amount, shares 1,350Average price/share, EUR3.6428Total cost, EUR4,917.78 The company holds a total of 5,667 of its own shares (ILKKA2) including the shares acquired on 9 December 2022. Detailed information concerning the acquisition is attached to this stock exchange release. On behalf of Ilkka Oyj DANSKE BANK A/S, FINLAND BRANCH Jonathan Nyberg Antti Väliaho Additional information Olli Pirhonen, CEO, Ilkka Oyj, tel. +358 40 766 5418 www.ilkka.com Attachment Ilkka buyback 9.12.2022